Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
about
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistanceA new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureusA rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine.Microbial resistance: novel screens for a contemporary problem.Brachyspira (Serpulina) hyodysenteriae gyrB mutants and interstrain transfer of coumermycin A(1) resistanceEffects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisFluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsMechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system.Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.gyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitroTopoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusMultilocus sequence typing and further genetic characterization of the enigmatic pathogen, Staphylococcus hominis.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Altering gene expression by aminocoumarins: the role of DNA supercoiling in Staphylococcus aureus.Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.Protective effect of Qnr on agents other than quinolones that target DNA gyrase.ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniaeContribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.Quinolone resistance due to reduced target enzyme expressionEvolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.An update on emerging therapies for urinary tract infections.Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistanceSmall-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
P2860
Q28361569-5861937A-D2BD-4830-8B1D-FC713762AE08Q28485591-0091F8EA-74DA-48F8-9684-5F1942EF8F0BQ30687068-002948CB-5AB7-4CE5-9A80-31C22EC7CA12Q30811045-85AB4ECE-49C4-4825-B1A5-B008652D5DBFQ30988207-5FFE9488-5533-49D5-9479-BC5737ABB9B9Q33698247-91629EF0-9DEF-4148-9447-EFB99597AE1EQ33976037-4CE362A6-F16A-414D-9BE2-FEE04A263435Q33976741-A7D12B3E-C7D6-41F0-93E7-68432C95DF04Q33976753-8041BDBE-6D68-4127-8C4B-1AE0ED1AA33DQ33979593-11CD1DD1-7A56-4F1C-8472-EB0B4E1AB602Q33980255-0A164270-5D92-4448-91AD-B848D3FDB4E3Q33980313-78D46B4C-9CD7-4035-9C1B-1218F77E1B8AQ33980747-687F8A1E-B289-4A1D-8F8D-DA829BC1AC18Q33980991-CD3215D9-57C2-4099-A1F9-3E0F88613AF5Q33983092-47CAB1C0-8F8A-4836-A723-F0CA218329B3Q33993653-C901603E-1BA8-4AAD-B0B2-B334794DF1A9Q34104362-D98652EE-728F-4E86-AC2A-58915A9CB165Q34142238-19589C15-D626-46CB-91E1-44072E79F6AFQ34446438-E748F75A-C89B-432D-897E-9E5BAA519588Q34720856-E8748D2E-576F-4B58-BE96-5667F398CB4EQ34725095-83353D3D-5303-4D76-9AA1-63E899F01EAEQ34776738-33C43560-D776-42C5-A920-B201A4EB93EAQ34885313-51DB2516-6381-45ED-8DF5-A7DA6A018117Q35148453-B89911B0-D7DF-4584-BFCE-817497C38F0FQ36048167-F02A5C98-001D-4240-831F-5777B847E6CCQ36158288-0526504C-9538-45CD-A9EF-548345F4D9BEQ36474350-2A2FDB05-7F9D-4985-9CB5-B2411359A403Q36757682-3E57B1C6-9363-45AF-9679-B5D56C742D28Q37062733-1D82F59E-0875-4E70-93C0-F2DBEC7A5B6FQ37624733-97606845-FD3B-4F5E-8FF3-968733297F08Q37880162-CEC66D23-3AB6-4ED8-A654-4E84BECF7223Q38751454-A6BB4791-FFAF-4707-8309-AEE8B8ECF79AQ39470064-B0811C73-66D3-4D8A-BA92-FB0C00C830E7Q39471404-73402147-CAA2-44CB-97F4-552FB82D28A3Q39478835-DC47E46F-C46D-4023-9487-3AA426CD8474Q39559340-E996BB2C-89BB-43A2-879A-4E1D667FD5CFQ39559548-C38C9083-2E3D-4FB4-B71C-E2F3E36F26E8Q39559732-3A4C13A3-F5A5-4AF3-9EFD-EA6AE990650EQ39559760-11E8CF12-D950-483E-B685-B7CBDD6B4C79Q39652375-F32A5BE7-F2EA-4E64-BC95-1D9E27050D16
P2860
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@ast
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@en
type
label
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@ast
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@en
prefLabel
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@ast
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@en
P2860
P356
P1476
Mutations in topoisomerase IV ...... inolone and coumarin activity.
@en
P2093
B Fournier
D C Hooper
P2860
P304
P356
10.1093/JAC/42.1.121
P407
P577
1998-01-01T00:00:00Z